CompletedInterventionalPhase 2Updated Aug 24, 2015
Patient Perception Study for AL-4943A | NCT01294969 | Trialant
CompletedInterventionalPhase 4Updated Dec 16, 2016
Patient Perception Study for AL-4943A
ClinicalTrials.gov ID
NCT01294969
Lead Sponsor
Alcon ResearchINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
47Actual
Last Update Posted
Dec 16, 2016Estimated
Start Date
Sep 2010
Primary Completion Date
Oct 2011Actual
Completion Date
Oct 2011Actual
Brief Summary
To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.
Allergic Conjunctivitis
AL-4943A
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of allergic conjunctivitis within last 24 months
Active signs and symptoms of ocular allergies
Exclusion Criteria:
Severe or serious ocular condition, ocular surgical intervention, ocular infection